Equities

hVIVO PLC

HVO:LSE

hVIVO PLC

Health CareHealth Care Providers
  • Price (GBX)28.00
  • Today's Change0.05 / 0.18%
  • Shares traded805.78k
  • 1 Year change69.70%
  • Beta1.5692
Data delayed at least 20 minutes, as of May 03 2024 16:35 BST.
More ▼

Profile data is unavailable for this security.

About the company

hVIVO plc is a United Kingdom-based specialist contract research organization (CRO). The Company is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. It provides end-to-end early clinical development services to its client base, which includes global biopharma companies. It offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. It offers additional clinical field trial services, such as patient recruitment and clinical trial site services. It runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.

  • Revenue in GBP (TTM)56.04m
  • Net income in GBP16.12m
  • Incorporated2011
  • Employees274.00
  • Location
    hVIVO PLC42 New RoadLONDON E1 2AXUnited KingdomGBR
  • Phone+44 28 9073 7900
  • Websitehttps://hvivo.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Faron Pharmaceuticals Oy0.00-26.54m108.23m34.00108.23m34.00
Futura Medical PLC3.10m-6.51m110.93m12.00110.93m12.00
Allergy Therapeutics plc53.26m-50.22m137.04m635.00137.04m635.00
4Basebio PLC354.00k-6.28m138.30m--138.30m--
Animalcare Group Plc74.35m1.20m141.85m220.00141.85m220.00
Avacta Group Plc16.03m-42.08m163.36m120.00163.36m120.00
Alliance Pharma plc170.05m-7.06m178.87m249.00178.87m249.00
hVIVO PLC56.04m16.12m190.50m274.00190.50m274.00
Bioventix PLC13.60m8.67m225.75m16.00225.75m16.00
Data as of May 03 2024. Currency figures normalised to hVIVO PLC's reporting currency: UK Pound GBX

Institutional shareholders

16.83%Per cent of shares held by top holders
HolderShares% Held
JPMorgan Asset Management (UK) Ltd.as of 21 Mar 202435.18m5.17%
Octopus Investments Ltd.as of 30 Apr 202424.01m3.53%
Canaccord Genuity Wealth Ltd.as of 29 Dec 202321.68m3.19%
Liontrust Investment Partners LLPas of 29 Mar 202410.37m1.52%
Thornbridge Investment Management LLPas of 31 Oct 20229.97m1.47%
Mandarine Gestion SAas of 30 Jun 20237.00m1.03%
Janus Henderson Investors UK Ltd.as of 31 Mar 20244.11m0.60%
River Global Investors LLPas of 31 Mar 20241.23m0.18%
Margetts Fund Management Ltd.as of 31 Aug 2023623.21k0.09%
Lazard Asset Management LLCas of 31 Mar 2024326.59k0.05%
More ▼
Data from 30 Jun 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.